• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LFVN

    Lifevantage Corporation

    Subscribe to $LFVN
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Corporation engages in the identification, research, development, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The company offers Protandim, a line of scientifically-validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, and hand creams, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. The company sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, and China. LifeVantage Corporation is headquartered in Sandy, Utah.

    IPO Year:

    Exchange: NASDAQ

    Website: lifevantage.com

    Recent Analyst Ratings for Lifevantage Corporation

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    See more ratings

    Lifevantage Corporation Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

    SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.* In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP an

    11/12/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod

    11/4/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period. Excluding the impact of foreign currency fluctuations, first quarter revenue increased approximately 0.3%;Revenue in the Americas increased 0.8%, and revenue in Asia/Pacific & Europe increased 0.4%.  Excluding the foreign currency fluctuations, first quarter revenue in Asia/Pacific & Eu

    11/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Empowers Consultants to "Love Life & Drive" at Momentum Academy 2025

    SALT LAKE CITY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of Momentum Academy 2025, a dynamic, high-impact event that brought together thousands of Consultants from across the U.S. from October 23-25 at the Hilton Anatole in Dallas, TX. This year's event centered around the theme: "Love Life & Drive" – inspiring Consultants to take the driver's seat in their businesses with purpose, speed, and unstoppable momentum. It also represents the first time Consultants from LoveBiome, who began integrati

    10/28/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce First Quarter Fiscal Year 2026 Results on November 4, 2025

    SALT LAKE CITY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2025, after the stock market closes on Tuesday, November 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours

    10/21/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in the LD Micro Main Event XIX on October 20, 2025

    SALT LAKE CITY, Oct. 13, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer will participate in the LD Micro Main Event XIX, to be held October 19-21, 2025 in San Diego, CA. Mr. Fife will meet with investors and present at approximately 5:30 p.m. Eastern Time on Monday, October 20, 2025. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor Relations website at https://lifevantage.gcs-web.com/ or directly here. A replay of the webc

    10/13/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Closing of LoveBiome Acquisition

    SALT LAKE CITY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the closing of its previously announced acquisition of LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions. Under the terms of the completed transaction, LifeVantage has acquired LoveBiome's critical operating assets essential to the microbiome health business, including the retention of key LoveBiome personnel. "We are pleased to have closed the LoveBiome acquisition and look forward to working with Kelly Ols

    10/2/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

    SALT LAKE CITY, Sept. 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Lytham Partners Fall 2025 Investor Conference, to be held virtually September 30, 2025. Mr. Fife and Mr. Aure will meet with investors and present at approximately 11:00 a.m. Eastern Time on Tuesday, September 30, 2025. A live webcast of their presentation will be accessible on the News & Events section of the Company's Investor Relations website at 

    9/22/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025

    SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025. Fourth Quarter Fiscal 2025 Summary*: Revenue of $55.1 million, an increase of 12.6% from the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter revenue increased approximately 11.6%;Revenue in the Americas increased 14.1% and revenue in Asia/Pacific & Europe increased 7.6%. Excluding foreign currency fluctuations, fourth quarter revenue in Asi

    9/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation SEC Filings

    View All

    Lifevantage Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Lifevantage Corp (0000849146) (Filer)

    11/12/25 4:35:42 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    11/4/25 4:06:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    11/4/25 4:05:03 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Lifevantage Corporation

    DEFA14A - Lifevantage Corp (0000849146) (Filer)

    9/19/25 4:23:59 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Lifevantage Corporation

    DEF 14A - Lifevantage Corp (0000849146) (Filer)

    9/19/25 4:14:41 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    9/4/25 4:06:47 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Lifevantage Corporation

    10-K - Lifevantage Corp (0000849146) (Filer)

    9/4/25 4:06:10 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    5/6/25 4:06:34 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    5/6/25 4:05:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    2/5/25 4:05:56 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $4,882 worth of shares (450 units at $10.85), increasing direct ownership by 0.39% to 117,217 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/18/25 4:36:17 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    6/17/25 4:11:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    5/13/25 4:11:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/24 5:00:17 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $3,618 worth of shares (351 units at $10.31), increasing direct ownership by 0.33% to 108,342 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/17/24 6:20:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mauro Garry Paul bought $11,848 worth of shares (1,600 units at $7.41), increasing direct ownership by 0.78% to 77,667 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/5/24 7:12:14 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $3,610 worth of shares (489 units at $7.38), increasing direct ownership by 0.45% to 107,991 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    6/18/24 4:09:45 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lewis Darwin bought $3,142 worth of shares (449 units at $7.00), increasing direct ownership by 0.42% to 107,502 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/18/24 7:14:42 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mauro Garry Paul gifted 30,893 shares, bought $1,128 worth of shares (199 units at $5.67) and received a gift of 30,893 shares, decreasing direct ownership by 29% to 77,067 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/6/24 8:15:40 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lewis Darwin bought $3,118 worth of shares (460 units at $6.78), increasing direct ownership by 0.43% to 107,053 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/19/23 9:00:06 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anbalagan Rajendran was granted 13,531 shares, increasing direct ownership by 129% to 23,999 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Latham Cynthia was granted 13,531 shares, increasing direct ownership by 26% to 64,879 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Greer Raymond B was granted 13,531 shares, increasing direct ownership by 14% to 112,819 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:59 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Beindorff Michael A sold $249,582 worth of shares (36,000 units at $6.93) and was granted 13,531 shares, increasing direct ownership by 55% to 35,389 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dayton Judd was granted 13,531 shares, increasing direct ownership by 40% to 47,162 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:42 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin was granted 13,531 shares, increasing direct ownership by 12% to 130,748 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:34 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Thompson Todd claimed ownership of 51,330 shares (SEC Form 3)

    3/A - Lifevantage Corp (0000849146) (Issuer)

    10/15/25 5:04:40 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Thompson Todd claimed ownership of 40,336 shares (SEC Form 3)

    3 - Lifevantage Corp (0000849146) (Issuer)

    10/3/25 4:42:59 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 1,720 shares, decreasing direct ownership by 1% to 136,986 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    10/3/25 4:11:54 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Neufeld Alissa covered exercise/tax liability with 1,283 shares, decreasing direct ownership by 1% to 116,977 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    10/3/25 4:11:48 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod

    11/4/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025. First Quarter Fiscal 2026 Summary*: Revenue was $47.6 million, an increase of 0.7% from the prior year period. Excluding the impact of foreign currency fluctuations, first quarter revenue increased approximately 0.3%;Revenue in the Americas increased 0.8%, and revenue in Asia/Pacific & Europe increased 0.4%.  Excluding the foreign currency fluctuations, first quarter revenue in Asia/Pacific & Eu

    11/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce First Quarter Fiscal Year 2026 Results on November 4, 2025

    SALT LAKE CITY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2025, after the stock market closes on Tuesday, November 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours

    10/21/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025

    SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025. Fourth Quarter Fiscal 2025 Summary*: Revenue of $55.1 million, an increase of 12.6% from the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter revenue increased approximately 11.6%;Revenue in the Americas increased 14.1% and revenue in Asia/Pacific & Europe increased 7.6%. Excluding foreign currency fluctuations, fourth quarter revenue in Asi

    9/4/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid September 16, 2025 to all stockholders of record at the close of business on September 8, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our pr

    8/28/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025

    SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2025, after the stock market closes on Thursday, September 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available appr

    8/21/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

    5/6/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

    SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

    5/6/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025

    SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after th

    4/22/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid March 17, 2025 to all stockholders of record at the close of business on March 3, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products wo

    2/5/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

    SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

    1/16/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

    SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice. "We are very excited to welcome Rajendran Anbalagan to the LifeVantage Board," said Ray Greer, Chairman. "Raj brings extensive technology experience along with a deep understanding of how to lever

    8/26/24 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

    SALT LAKE CITY, July 22, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, will host Open House calls on July 23 and 24, for anyone wanting to learn more about LifeVantage, its activating products, and the Company's industry-leading compensation plan designed to meet modern sharers by supporting both product sellers and team builders. The Open House call on the 23rd will feature a Q&A with LifeVantage President and CEO, Steve Fife, Chief Sales Officer, Kristen Cunningham, and Regional Vice President of Sales, Jake Hines. The discussion will include the e

    7/22/24 6:27:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appoints Dayton Judd to the Board of Directors

    SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these dis

    2/15/24 4:05:00 PM ET
    $FTLF
    $LFVN
    $OPXS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Electronic Components

    LifeVantage Appoints Raymond Greer as Chairman of the Board of Directors

    SALT LAKE CITY, Nov. 27, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes, today announced that the Board of Directors has appointed Raymond Greer as Chairman of the Board. He succeeds Garry Mauro, who will continue to serve as a member of the Board of Directors. "We want to thank Garry for his many contributions while serving as Chairman. He provided critical leadership around our efforts to revamp the management team over the past several years and helped to shape our comprehensive strategic LV360 transformation," said Steve Fife, President an

    11/27/23 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appoints Cindy Latham to Board of Directors

    SALT LAKE CITY, Feb. 17, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) today announced the appointment of Cindy Latham to the Company's Board of Directors. Latham is a senior-level marketing executive with over 30 years of experience leading global marketing, research and development, and product teams in direct selling organizations. Garry Mauro, Chairman, said of the appointment: "We are delighted to welcome Cindy to the LifeVantage Board. She is a proven leader with outstanding industry experience and a strong track record of driving growth." "It's an honor to join the Board at this time, to help shape new strategies and tactics that leverage the incredible power

    2/17/22 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appoints Carl Aure as Chief Financial Officer

    SALT LAKE CITY, Oct. 25, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer. Mr. Aure brings more than 24 years of finance and accounting experience including over 15 years in the direct selling industry. He will join the Company on October 25, 2021. "We are pleased to welcome Carl to the LifeVantage team. His deep financial expertise along with an extensive background in direct selling and international operations make him the ideal candidate to lead all aspects of finance, accounting, tax and treasury," said Steve Fife, President and Chief Executive Officer of LifeVantage. "Carl is also a proven leader w

    10/25/21 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Appointment of Chief Executive Officer

    SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that its Board of Directors has named Steven Fife as President and Chief Executive Officer. Mr. Fife’s appointment is effective immediately as he has been serving as Interim Chief Executive Officer since September, 2020. He also joins the Board of Directors. “Steve is a highly experienced and accomplished executive with a deep understanding of our business and a clear vision for the future,” said Garry Mauro, the Company’s Chairman of the Board. Mauro continued, “Steve has been instrumental in the growth and success of the Company since joining as CFO in 2017. As we conducted our sear

    2/2/21 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lifevantage Corporation (Amendment)

    SC 13G/A - Lifevantage Corp (0000849146) (Subject)

    2/13/24 10:32:16 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    11/14/23 3:19:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    11/14/23 3:17:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    8/11/23 9:53:32 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    8/11/23 9:17:46 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Lifevantage Corporation

    SC 13D - Lifevantage Corp (0000849146) (Subject)

    5/15/23 2:01:44 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lifevantage Corporation (Amendment)

    SC 13G/A - Lifevantage Corp (0000849146) (Subject)

    2/13/23 10:59:24 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care